These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 32373649)

  • 1. Preclinical Toxicology of rQNestin34.5v.2: An Oncolytic Herpes Virus with Transcriptional Regulation of the ICP34.5 Neurovirulence Gene.
    Chiocca EA; Nakashima H; Kasai K; Fernandez SA; Oglesbee M
    Mol Ther Methods Clin Dev; 2020 Jun; 17():871-893. PubMed ID: 32373649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor.
    Kambara H; Okano H; Chiocca EA; Saeki Y
    Cancer Res; 2005 Apr; 65(7):2832-9. PubMed ID: 15805284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA demethylating agents synergize with oncolytic HSV1 against malignant gliomas.
    Okemoto K; Kasai K; Wagner B; Haseley A; Meisen H; Bolyard C; Mo X; Wehr A; Lehman A; Fernandez S; Kaur B; Chiocca EA
    Clin Cancer Res; 2013 Nov; 19(21):5952-9. PubMed ID: 24056786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.
    Liu BL; Robinson M; Han ZQ; Branston RH; English C; Reay P; McGrath Y; Thomas SK; Thornton M; Bullock P; Love CA; Coffin RS
    Gene Ther; 2003 Feb; 10(4):292-303. PubMed ID: 12595888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of glioblastoma with current oHSV variants reveals differences in efficacy and immune cell recruitment.
    Jackson JW; Hall BL; Marzulli M; Shah VK; Bailey L; Chiocca EA; Goins WF; Kohanbash G; Cohen JB; Glorioso JC
    Mol Ther Oncolytics; 2021 Sep; 22():444-453. PubMed ID: 34553031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STAT3 activation promotes oncolytic HSV1 replication in glioma cells.
    Okemoto K; Wagner B; Meisen H; Haseley A; Kaur B; Chiocca EA
    PLoS One; 2013; 8(8):e71932. PubMed ID: 23936533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting IGF2 to reprogram the tumor microenvironment for enhanced viro-immunotherapy.
    Noh MH; Kang JM; Miller AA; Nguyen G; Huang M; Shim JS; Bueso-Perez AJ; Murphy SA; Rivera-Caraballo KA; Otani Y; Kim E; Yoo SH; Yan Y; Banasavadi-Siddegowda Y; Nakashima H; Chiocca EA; Kaur B; Zhao Z; Lee TJ; Yoo JY
    Neuro Oncol; 2024 Sep; 26(9):1602-1616. PubMed ID: 38853689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trial links oncolytic immunoactivation to survival in glioblastoma.
    Ling AL; Solomon IH; Landivar AM; Nakashima H; Woods JK; Santos A; Masud N; Fell G; Mo X; Yilmaz AS; Grant J; Zhang A; Bernstock JD; Torio E; Ito H; Liu J; Shono N; Nowicki MO; Triggs D; Halloran P; Piranlioglu R; Soni H; Stopa B; Bi WL; Peruzzi P; Chen E; Malinowski SW; Prabhu MC; Zeng Y; Carlisle A; Rodig SJ; Wen PY; Lee EQ; Nayak L; Chukwueke U; Gonzalez Castro LN; Dumont SD; Batchelor T; Kittelberger K; Tikhonova E; Miheecheva N; Tabakov D; Shin N; Gorbacheva A; Shumskiy A; Frenkel F; Aguilar-Cordova E; Aguilar LK; Krisky D; Wechuck J; Manzanera A; Matheny C; Tak PP; Barone F; Kovarsky D; Tirosh I; Suvà ML; Wucherpfennig KW; Ligon K; Reardon DA; Chiocca EA
    Nature; 2023 Nov; 623(7985):157-166. PubMed ID: 37853118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Augmented therapeutic efficacy of an oncolytic herpes simplex virus type 1 mutant expressing ICP34.5 under the transcriptional control of musashi1 promoter in the treatment of malignant glioma.
    Kanai R; Tomita H; Hirose Y; Ohba S; Goldman S; Okano H; Kawase T; Yazaki T
    Hum Gene Ther; 2007 Jan; 18(1):63-73. PubMed ID: 17238803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurovirulent factor ICP34.5 uniquely expressed in the herpes simplex virus type 1 Delta gamma 1 34.5 mutant 1716.
    Holman HA; MacLean AR
    J Neurovirol; 2008 Jan; 14(1):28-40. PubMed ID: 18300073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional genomic analysis of herpes simplex virus type 1 counteraction of the host innate response.
    Pasieka TJ; Baas T; Carter VS; Proll SC; Katze MG; Leib DA
    J Virol; 2006 Aug; 80(15):7600-12. PubMed ID: 16840339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Herpes Simplex Virus 1 γ34.5 in the Regulation of IRF3 Signaling.
    Manivanh R; Mehrbach J; Knipe DM; Leib DA
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28904192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ICP34.5 mutants of herpes simplex virus type 1 strain 17syn+ are attenuated for neurovirulence in mice and for replication in confluent primary mouse embryo cell cultures.
    Bolovan CA; Sawtell NM; Thompson RL
    J Virol; 1994 Jan; 68(1):48-55. PubMed ID: 8254758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ICP34.5 protein of herpes simplex virus facilitates the initiation of protein translation by bridging eukaryotic initiation factor 2alpha (eIF2alpha) and protein phosphatase 1.
    Li Y; Zhang C; Chen X; Yu J; Wang Y; Yang Y; Du M; Jin H; Ma Y; He B; Cao Y
    J Biol Chem; 2011 Jul; 286(28):24785-92. PubMed ID: 21622569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An avirulent ICP34.5 deletion mutant of herpes simplex virus type 1 is capable of in vivo spontaneous reactivation.
    Perng GC; Thompson RL; Sawtell NM; Taylor WE; Slanina SM; Ghiasi H; Kaiwar R; Nesburn AB; Wechsler SL
    J Virol; 1995 May; 69(5):3033-41. PubMed ID: 7707530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultrastructural analysis of ICP34.5- herpes simplex virus 1 replication in mouse brain cells in vivo.
    Mehta H; Muller J; Markovitz NS
    J Virol; 2010 Nov; 84(21):10982-90. PubMed ID: 20702618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus.
    Kambara H; Saeki Y; Chiocca EA
    Cancer Res; 2005 Dec; 65(24):11255-8. PubMed ID: 16357128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A virus with a mutation in the ICP4-binding site in the L/ST promoter of herpes simplex virus type 1, but not a virus with a mutation in open reading frame P, exhibits cell-type-specific expression of gamma(1)34.5 transcripts and latency-associated transcripts.
    Lee LY; Schaffer PA
    J Virol; 1998 May; 72(5):4250-64. PubMed ID: 9557715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant.
    Ikeda K; Wakimoto H; Ichikawa T; Jhung S; Hochberg FH; Louis DN; Chiocca EA
    J Virol; 2000 May; 74(10):4765-75. PubMed ID: 10775615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors.
    Kanai R; Zaupa C; Sgubin D; Antoszczyk SJ; Martuza RL; Wakimoto H; Rabkin SD
    J Virol; 2012 Apr; 86(8):4420-31. PubMed ID: 22345479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.